Unidose Nasal Spray for Migraine Therapy

There are over 1 billion people that suffer from migraines globally. Bona’s Unidose Nasal Spray has provided patients effective drug delivery system for this unmet demand. It bypasses gastrointestinal absorption through direct vascular delivery in the nasal mucosa. The emergence of single-dose nasal sprays marks a paradigm shift in acute migraine management, offering rapid onset of action without the need for systemic administration.

The clinical advantages of nasal sprays stem from their unique pharmacokinetics. The nasal cavity's rich vascular network enables rapid drug absorption into the bloodstream within minutes, crucial for aborting migraine attacks during the early pain phase. Compared to oral triptans requiring 30-60 minutes for effect, nasal formulations like Zavegepant demonstrate pain relief within 15-30 minutes, with efficacy rates 60% higher than placebo at 2 hours. This speed is particularly valuable for patients experiencing nausea or vomiting, where oral medications may be impractical.

The single-dose design ensures standardized administration, eliminating dose calculation errors while maintaining consistent plasma concentrations. Furthermore, nasal sprays avoid first-pass liver metabolism, potentially reducing systemic side effects while achieving comparable or superior efficacy to injectable alternatives.

Bona Pharma has developed an innovative unidose spray system, 100mcl dosage, or custom, that is ideal for administering migraine medication. To facilitate brand customers to validate it, BONA Pharma purchases original glass vials from European supplier. For more information, please refer to www.bona-cn.com, or contact Bona Pharma.